Apolizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Apolizumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target HLA-DR beta
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
 NYesY (what is this?)  (verify)

Apolizumab is a humanized monoclonal antibody intended for use in hematologic cancers.[1][2] Development was abandoned in 2005, and there are no current clinical trials into its use.[3]

References[edit]

  1. ^ Bayes M; Rabasseda X; Prous J (2003). "Gateways to clinical trials.". Methods Find Exp Clin Pharmacol. 25 (9): 747–71. PMID 14685303. 
  2. ^ Rech, J; Repp, R; Rech, D; Stockmeyer, B; Dechant, M; Niedobitek, G; Gramatzki, M; Valerius, T (2006). "A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study.". Leukemia & lymphoma. 47 (10): 2147–54. PMID 17071489. doi:10.1080/10428190600757944. 
  3. ^ http://adisinsight.springer.com/drugs/800006415